Clinical Trial Listings

Formal Study Name:  Engendering Reproductive Health Within Oncologic Survivorship
Anatomic Site:
Any
Histology:
Pre-Menopausal Women (18-55) with Cancer
Stage:
Any
Trial Type:
Quality of Life & Supportive Care
Principal Investigator:
Alyssa Throckmorton, MD
Formal Study Name:  A Pragmatic trial to Improve Colony Stimulating Factor for Use in Cancer
Anatomic Site:
ANY
Histology:
Breast Cancer, Colorectal, Non-Small Cell Lung Cancer (NSCLC), Non-Small Cell Lung Carcinoma
Stage:
Breast: Stage 0, Stage IA, Stage IB, Stage IIA, Stage IIB, Stage IIIA, Stage IIIB, Stage IIIC, Stage IV Colorectal: Stage 0, Stage I, Stage IIA, Stage IIB, Stage IIC, Stage IIIA, Stage IIIB, Stage IIIC, Stage IVA, Stage IVB NSCLC: Stage 0, Stage IIA, Stage IIB, Stage IV Non-Small Cell Lung Carcinoma: Stage IA, Stage IB, Stage IIA, Stage IIB
Treatment Phase:  Patient has current diagnosis. Patient has not had systemic therapy for their diagnosis (or not had systemic therapy for different diagnosis within 180 days)
Trial Type:
Prevention
Principal Investigator:
Alexander Quesenberry, PharmD
Formal Study Name:  Molecular Analysis for Therapy Choice (MATCH)
Anatomic Site:
Any
Histology:
Advanced Malignant Neoplasm, Lymphoma, Recurrent Plasma Cell Myeloma, Recurrent Solid Neoplasm, Refractory Malignant Neoplasm, Refractory Plasma Cell Myeloma
Mutation:
EGFR, HER2, EGFR T790M, BRAF V600E/R/K/D, PIK3CA, PTEN, PTEN deletion, PTEN loss, HER2 amplification, BRAF fusion, BRAF non-V600, NF 1, GNAQ, GNA11, SMO, PTCH1, NF2 inactivating, cKIT exon 9, cKIT exon 11, cKIT exon 13, cKIT exon 14, FGFR pathway aberrations, DDR2 S768R, I638F, L239R, Akt, NRAS in codon 12, NRAS in codon 13, NRAS in codon 61, CCND1, 2, or 3 amplification with Rb by IHC, Loss of MLH1 or MSH2 by IHC.
Stage:
Advanced
Treatment Phase:  Patient must have histologically documented solid tumors or confirmed diagnosis of lymphoma or multiple myeloma requiring therapy. Patients must have progressed following at least one line of standard systemic therapy; no standard treatment exists for their disease. Must have measurable disease
Trial Phase:
II
Trial Type:
Treatment
Principal Investigator:
Donald Gravenor, MD
Formal Study Name:  Communication and Education in Tumor Profiling: A Randomized Study of Pre-disclosure Genetic Education v. Usual Care in Tumor Profiling for Adv. Cancer and a Pilot Study of Remote Genetic Counseling for Participants with Potential Germline Mutations Identified on Tumor Profiling
Anatomic Site:
Any
Histology:
Advanced Malignant Neoplasm, Locally Advanced Malignant Neoplasm
Mutation:
Potential Germline mutations
Stage:
Advanced
Treatment Phase:  Patients must have a potential germline mutation – as determined by MATCH trial (EAY131)
Principal Investigator:
Donald Gravenor, MD
Formal Study Name:  The National Myelodysplastic Syndromes (MDS) Study
Anatomic Site:
Blood and Marrow
Histology:
Myelodysplastic Syndromes (MDS)
Stage:
Any
Treatment Phase:  Patients suspected to have MDS and are undergoing diagnostic work-up with planned bone marrow assessments to confirm MDS or to evaluate disease status.
Trial Type:
Observational
Principal Investigator:
Salil Goorha, MD
Locations Where Open:
Formal Study Name:  A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy
Anatomic Site:
Breast
Histology:
Breast Cancer with Positive Sentinel Lymph Node(s)
Stage:
Stage II, Stage IIIA
Treatment Phase:  No previous neoadjuvant endocrine or radiation therapy. No SLN surgery.
Trial Phase:
III
Trial Type:
Treatment
Principal Investigator:
Lindi VanderWalde, MD
Formal Study Name:  Early Onset Malignancies Initiative (EOMI): Molecular profiling of Breast, Prostate, Colorectal, Liver, Kidney, and Multiple Myeloma among Racially and Ethnically Diverse Populations
Anatomic Site:
Any
Histology:
Breast Cancer, Prostate Cancer, Colorectal Cancer, Liver Cancer, Kidney Cancer, Multiple Myeloma
Principal Investigator:
Philip Lammers, MD
Locations Where Open:
Formal Study Name:  Patient-Derived Models Tissue Procurement Protocol for the National Cancer Institute (NCI)
Anatomic Site:
Any
Trial Type:
Observational
Principal Investigator:
Raymond Osarogiagbon, MD
Formal Study Name:  A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
Anatomic Site:
Breast
Histology:
Breast Carcinoma
Mutation:
HR+, HER2-
Stage:
IB, IIA, IIB
Treatment Phase:  The participant must have undergone definitive surgical treatment for the current malignancy. Must not have received more than 12 weeks of adjuvant endocrine therapy following his/her last non-endocrine therapy (surgery, chemotherapy, or radiation).
Trial Phase:
III
Trial Type:
Treatment
Principal Investigator:
Aleksandar Jankov, MD
Formal Study Name:  A Phase II Trial Assessing the Accuracy of Tumor Bed Biopsies in Predicting Pathologic Response in Patients With Clinical/Radiologic Complete Response After Neoadjuvant Chemotherapy in Order to Explore the Feasibility of Breast Conserving Treatment Without Surgery
Anatomic Site:
Breast
Histology:
Invasive Breast Carcinoma
Stage:
II, IIA, IIB, IIIA
Treatment Phase:  Patients must have achieved a complete or near complete radiologic tumor response on breast imaging with mammogram, ultrasound, and MRI. Patients must be undergoing breast conserving therapy
Trial Phase:
II
Trial Type:
Interventional
Principal Investigator:
Interventional
Locations Where Open:
Formal Study Name:  Prospective Evaluation of Carvedilol in Prevention of Cardiac Toxicity in Patients With Metastatic HER-2+ Breast Cancer, Phase III
Anatomic Site:
Breast
Histology:
Breast Carcinoma
Mutation:
HER2+
Stage:
IV, Recurrent Breast Carcinoma
Treatment Phase:  Must have metastatic breast cancer and initiating or continuing trastuzumab-based HER-2 targeted therapy without concurrent anthracyclines in first or second line setting
Trial Phase:
III
Trial Type:
Supportive Care
Principal Investigator:
Sailendra Vasireddy, MD
Formal Study Name:  Tomosynthesis Mammographic Imaging Screening Trial (TMIST)
Anatomic Site:
Breast
Treatment Phase:  Patients must not have previous personal history of breast cancer including ductal carcinoma in situ. Patients must be scheduled for, or have intent to schedule, a screening mammogram
Trial Phase:
III
Trial Type:
Screening/Interventional
Principal Investigator:
Lynn Gayden, MD
Locations Where Open:
Formal Study Name:  A211401
Anatomic Site:
Lung
Treatment Phase:  Newly diagnosed with lung cancer and have sought a surgical consult related to lung cancer diagnosis. Must be motivated to stop smoking
Trial Phase:
III
Trial Type:
Supportive Care/Smoking Cessation
Principal Investigator:
Todd Robbins, MD
Formal Study Name:  Maintenance Systemic Therapy Versus Consolidative Stereotactic Body Radiation Therapy (SBRT) Plus Maintenance Systemic Therapy for Limited Metastatic Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase II/III Trial
Anatomic Site:
Lung
Histology:
Non-Small Cell Lung Carcinoma
Stage:
Recurrent, Stage IV
Treatment Phase:  Must have received first-line/induction chemotherapy (4 cycles) and achieved stable disease or a partial response
Trial Phase:
II
Trial Type:
Treatment
Principal Investigator:
Raymond Osarogiagbon, MD
Locations Where Open:
Formal Study Name:  Procurement of Human Biospecimens for Current and Future Medical Research
Anatomic Site:
Lung
Histology:
Non-Small Cell Lung Cancer
Stage:
Any
Treatment Phase:  Has not had any previous treatment or has not had any treatment within the last 6 months
Principal Investigator:
Todd Robbins, MD
Locations Where Open:
Formal Study Name:  Implementation Of Smoking Cessation Services Within NCI NCORP Community Sites With Organized Lung Cancer Screening Programs
Anatomic Site:
Lung
Treatment Phase:  Must not have used a form of tobacco dependence treatment including bupropion, varenicline, and nicotine replacement within the last 30 days
Trial Type:
Treatment
Principal Investigator:
Robert Optican, MD
Locations Where Open:
Formal Study Name:  A Randomized Double-Blind Phase III Study of Ibrutinib During and Following Autologous Stem Cell Transplantation Versus Placebo in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma of the Activated B-Cell Subtype
Anatomic Site:
Blood and Marrow
Histology:
Diffuse Large B-Cell Lymphoma Activated B-Cell Type, Diffuse Large B-Cell Lymphoma, High Grade B-Cell Lymphoma, Recurrent Burkitt Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Refractory Burkitt Lymphoma, Refractory Diffuse Large B-Cell Lymphoma
Treatment Phase:  Patient must have progressed or be refractory to prior anthracycline-containing chemotherapy (e.g. R-CHOP, DA-EPOCH-R, etc); No more than 3 prior regimens for large cell component (e.g. one induction and two salvage therapies)
Trial Phase:
III
Trial Type:
Treatment
Principal Investigator:
Muhammad Raza, MD
Formal Study Name:  Prospective Research Assessment in Multiple Myeloma: An Observational Evaluation (PREAMBLE)
Anatomic Site:
Blood and Marrow
Histology:
Multiple Myeloma
Treatment Phase:  Have received at least one prior line of therapy for Multiple Myeloma
Trial Type:
Observational
Principal Investigator:
Salil Goorha, MD
Formal Study Name:  A Phase 3B Randomized Study of Lenalidomide (CC-5013) Plus Rituximab Maintenance Therapy Followed by Lenalidomide Single-Agent Maintenance Versus Rituximab in Subjects With Relapsed/Refractory Follicular, Marginal Zone, or Mantle Cell Lymphoma
Anatomic Site:
Blood and Marrow
Histology:
Non-Hodgkin Lymphoma
Treatment Phase:  Must have documented relapsed, refractory or Progressive Disease after last treatment with systemic therapy
Trial Phase:
III
Trial Type:
Treatment
Principal Investigator:
Salil Goorha, MD
Formal Study Name:  A Simplified Patient Care Strategy to Decrease Early Deaths in Acute Promyelocytic Leukemia (APL)
Anatomic Site:
Blood and Marrow
Histology:
Acute Promyelocytic Leukemia With PML-RARA, t(15;17)
Treatment Phase:  Referrals must be made as early as possible but no later than 5 calendar days after ATRA therapy is initiated; consent can be obtained up till day 7 or earlier
Trial Type:
Prevention
Principal Investigator:
Salil Goorha, MD
Formal Study Name:  A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR-1202 With or Without Bendamustine and TGR-1202 Alone in Patients With Previously Treated Non-Hodgkin's Lymphoma
Anatomic Site:
Blood and Marrow
Histology:
Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Marginal Zone Lymphoma, Small Lymphocytic Lymphoma, Mantle Cell Lymphoma
Treatment Phase:  Relapsed or refractory to prior standard therapy
Trial Phase:
II/III
Trial Type:
Treatment
Principal Investigator:
Salil Goorha, MD
Locations Where Open:
Formal Study Name:  DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumor
Anatomic Site:
Any
Histology:
Acinar Cell Carcinoma, Adenoid Cystic Carcinoma, Adrenal Cortex Carcinoma, Adrenal Gland Pheochromocytoma, Anal Canal, Neuroendocrine Carcinoma, Anal Canal Undifferentiated Carcinoma, Appendix Mucinous Adenocarcinoma, Bartholin Gland Transitional, Cell Carcinoma, Bladder Adenocarcinoma, Cervical Adenocarcinoma, Cholangiocarcinoma, Chordoma, Colorectal Squamous Cell, Carcinoma, Desmoid-Type Fibromatosis, Endometrial Transitional Cell Carcinoma, Endometrioid Adenocarcinoma, Esophageal Neuroendocrine Carcinoma, Esophageal Undifferentiated Carcinoma, Extrahepatic Bile Duct Carcinoma, Fallopian Tube Adenocarcinoma, Fallopian Tube Transitional Cell Carcinoma, Fibromyxoid Tumor, Gastric Neuroendocrine Carcinoma, Gastric Squamous Cell Carcinoma, Gastrointestinal Stromal Tumor, Giant Cell Carcinoma, Intestinal Neuroendocrine Carcinoma, Intrahepatic Cholangiocarcinoma, Lung Carcinoid Tumor, Lung Sarcomatoid Carcinoma, Major Salivary Gland Carcinoma, Malignant Odontogenic Neoplasm, Malignant Peripheral Nerve Sheath Tumor, Malignant Testicular Sex Cord-Stromal Tumor, Metaplastic Breast Carcinoma Metastatic Malignant Neoplasm of Unknown Primary Origin, Minimally Invasive Lung Adenocarcinoma, Mixed Mesodermal (Mullerian) Tumor, Mucinous Adenocarcinoma, Mucinous Cystadenocarcinoma, Nasal Cavity Adenocarcinoma, Nasal Cavity Carcinoma, Nasopharyngeal Carcinoma, Nasopharyngeal Papillary Adenocarcinoma, Nasopharyngeal Undifferentiated Carcinoma, Oral Cavity Carcinoma, Oropharyngeal Undifferentiated Carcinoma, Ovarian Adenocarcinoma, Ovarian Germ Cell Tumor, Ovarian Mucinous Adenocarcinoma, Ovarian Squamous Cell Carcinoma, Ovarian Transitional Cell Carcinoma, Pancreatic Acinar Cell Carcinoma, Pancreatic Neuroendocrine Carcinoma, Paraganglioma, Paranasal Sinus Adenocarcinoma, Paranasal Sinus Carcinoma, Parathyroid Gland Carcinoma, Pituitary Gland Carcinoma, Placental Choriocarcinoma, Placental-Site Gestational Trophoblastic Tumor, Primary Peritoneal High Grade Serous Adenocarcinoma, Pseudomyxoma Peritonei, Rare Disorder, Scrotal Squamous Cell Carcinoma, Seminal Vesicle Adenocarcinoma, Seminoma, Serous Cystadenocarcinoma, Small Intestinal Adenocarcinoma, Small Intestinal Squamous Cell Carcinoma. Spindle Cell Neoplasm, Squamous Cell Carcinoma of the Penis, Teratoma With Malignant Transformation, Testicular Non-Seminomatous Germ Cell Tumor, Thyroid Gland Carcinoma, Tracheal Carcinoma, Transitional Cell Carcinoma, Undifferentiated Gastric Carcinoma, Ureter Adenocarcinoma, Ureter Squamous Cell Carcinoma, Urethral Adenocarcinoma, Urethral Squamous Cell Carcinoma, Vaginal Adenocarcinoma, Vaginal Squamous Cell Carcinoma (Not Otherwise Specified), Vulvar Carcinoma
Stage:
Any
Treatment Phase:  Patients must have progressed following at least one line of standard systemic therapy or patients for whose disease no standard treatment exists that has been shown to prolong overall survival
Trial Phase:
II
Trial Type:
Treatment
Principal Investigator:
Donald Gravenor, MD
Formal Study Name:  Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women With Early Breast Cancer
Anatomic Site:
Breast
Histology:
Invasive Breast Carcinoma
Mutation:
Her-2 negative
Stage:
ER and PR negative: T2 or T3 N0, or T0-3 N1-3; ER and/or PR positive: T0-3 N1-3, or T3 N0
Treatment Phase:  Patients must have histologically confirmed invasive breast cancer. All adjuvant or neoadjuvant chemotherapy, radiation, and surgery must be completed; must have sentinel lymph node biopsy and/or axillary lymph node dissection.
Trial Phase:
III
Trial Type:
Treatment
Principal Investigator:
Aleksandar Jankov, MD
Formal Study Name:  A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for Node Positive HER2 Negative Breast Cancer: The ABC Trial
Anatomic Site:
Breast
Histology:
Breast Carcinoma, Breast Cancer
Mutation:
Any Estrogen/Progesterone status, HER-2 negative
Stage:
Node-positive, anatomic stage II or III
Treatment Phase:  Patients must be within one year of diagnosis and free of recurrence. Histologic documentation of node positivity is required. Chemotherapy or radiation therapy must be completed. Concurrent hormonal therapy is allowed.
Trial Phase:
III
Trial Type:
Treatment
Principal Investigator:
Alyssa Throckmorton, MD
Formal Study Name:  Alternate Approaches for Clinical Stage II or III Estrogen Receptor Positive Breast Cancer Neoadjuvant Treatment (ALTERNATE) in Postmenopausal Women: A Phase III Study
Anatomic Site:
Breast
Histology:
Breast Carcinoma, Breast Cancer
Mutation:
HER2-negative, ER-positive
Stage:
Carcinoma: Invasive Ductal, Invasive Lobular; Cancer: Stage II, Stage IIIA, Stage IIIB, Stage IIIC
Treatment Phase:  Postmenopausal women with pathologic confirmation of invasive breast cancer diagnosed by core needle biopsy.
Trial Phase:
III
Trial Type:
Treatment
Principal Investigator:
Alyssa Throckmorton, MD
Formal Study Name:  A Randomized Ph. III Trial of Endocrine Therapy plus Entinostat/Placebo in Patients with Hormone Receptor+ Advanced Breast Cancer
Anatomic Site:
Breast
Histology:
Breast Carcinoma, Breast Cancer
Mutation:
HER2/NEU Negative; Estrogen Receptor Positive; Progesterone Receptor Positive
Stage:
Carcinoma: Male, Recurrent; Cancer: Stage IIIB, Stage IIIC, Stage IV
Treatment Phase:  ER and/or PR positive histologically confirmed adenocarcinoma at any time during treatment prior to study. May have received only one prior chemotherapy regiment.
Trial Phase:
III
Trial Type:
Treatment
Principal Investigator:
Sailendra Vasireddy, MD
Formal Study Name:  A Randomized Phase III Post-Operative Trial of Platinum Based Chemo vs. Observation in Patients with Residual Triple- Basal-Like Breast Ca post Neoadj. Chemo
Anatomic Site:
Breast
Histology:
Invasive Breast Carcinoma, Breast Cancer
Mutation:
Estrogen Receptor Negative, HER2/Neu Negative, Progesterone Receptor Negative, Triple Negative
Stage:
Stage IIA, Stage IIB, Stage IIIA, Stage IIIB, Stage IIIC
Treatment Phase:  Must have histologically confirmed triple negative invasive breast cancer, clinical stage II-III at diagnosis. Patients must have completed neoadjuvant regimen and completed definitive resection of primary tumor.
Trial Phase:
III
Trial Type:
Treatment
Principal Investigator:
Drew Dill, MD
Formal Study Name:  A Randomized Ph.3 Trial Evaluating Post-Mastectomy Chest Wall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy
Anatomic Site:
Breast
Histology:
Breast Cancer
Stage:
Stage II, Stage III
Treatment Phase:  Patient must have clinically T1-3, NI breast cancer at time of diagnosis (before neoadjuvant therapy), estrogen receptor analysis performed before neoadjuvant chemotherapy, and must have completed a minimum of 12 weeks of standard neoadjuvant chemotherapy.
Trial Type:
Treatment
Principal Investigator:
Alyssa Throckmorton, MD
Formal Study Name:  Phase II Randomized Placebo-Controlled Trial of Cisplatin With or Without ABT-888 (Veliparib) in Metastatic Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer
Anatomic Site:
Breast
Histology:
Breast Carcinoma
Mutation:
Estrogen Negative, Progesterone Negative, HER2/NEU Negative, and/or BRCA1 or BRCA2 Mutation
Stage:
Stage IV
Treatment Phase:  Patients must have measurable or non-measurable disease. Must have had =< 1 prior cytotoxic regimen for metastatic disease and completed any prior radiation therapy or hormonal therapy.
Trial Phase:
II
Trial Type:
Treatment
Principal Investigator:
Sailendra Vasireddy, MD
Formal Study Name:  A Phase 3 Randomized Placebo Controlled Clinical Trial of Donepezil in Chemotherapy Exposed Breast Cancer Survivors With Cognitive Impairment
Anatomic Site:
Breast
Histology:
Invasive Breast Cancer
Stage:
History of breast cancer
Treatment Phase:  Must have completed at least 4 cycles of adjuvant/neo-adjuvant cytoxic chemotherapy. No evidence of suspected recurrent or metastatic disease. Self-reported cognitive complaint and documented measured memory deficit.
Trial Phase:
III
Trial Type:
Treatment
Principal Investigator:
Drew Dill, MD
Formal Study Name:  A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients With Stage 0-III Colon or Rectal Cancer, Phase III - Preventing Adenomas of the Colon With Eflornithine and Sulindac (PACES)
Anatomic Site:
GI
Histology:
Colon Cancer, Rectal Cancer
Stage:
Stage 0, I, II, or III
Treatment Phase:  Patients must have received primary resection 1 year previously and be at least 30 days from completion of adjuvant chemotherapy and radiation therapy.
Trial Phase:
III
Trial Type:
Prevention
Principal Investigator:
Stephen Behrman, MD
Formal Study Name:  Implementation of a Prospective Financial Impact Assessment Tool in Patients With Metastatic Colorectal Cancer
Anatomic Site:
GI
Histology:
Colon Cancer, Rectal Cancer
Stage:
Colon Cancer: Stage IVA, Stage IVB; Rectal Cancer: Stage IVA, Stage IVB
Treatment Phase:  Patients must have newly diagnosed metastatic colon or rectal cancer (de novo metastatic diagnosis or metastatic recurrence) after prior treatment for stage I-III disease
Trial Type:
Observational
Principal Investigator:
Peter Carter, MD
Formal Study Name:  Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Anatomic Site:
Lung
Histology:
Non-Small Cell Lung Cancer (NSCLC), Non-Small Cell Lung Carcinoma
Mutation:
EGFR exon 19 deletion; L858R mutation
Stage:
NSCLC: Stage IB, Stage IIA, Stage IIB; Carcinoma: Stage IIA
Treatment Phase:  Previously registered to A151216 with an EGFR exon 19 deletion or L858R mutation, have complete recovery from surgery and standard post-operative therapy.
Trial Phase:
III
Trial Type:
Treatment
Principal Investigator:
Todd Robbins, MD
Formal Study Name:  Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST screening trial)
Anatomic Site:
Lung
Histology:
Squamous, Non-Small Cell Lung Cancer (NSCLC), Large Cell Lung Carcinoma
Stage:
Squamous & SCLC: Stage IB, Stage IIA, Stage IIB, Stage IIIA
Treatment Phase:  Patients with suspected diagnosis of resectable or completely resected NSCLC and have not received neoadjuvant therapy for this cancer.
Trial Type:
Screening
Principal Investigator:
Todd Robbins, MD
Formal Study Name:  Phase III Comparison of Thoracic Radiotherapy Regimens in Patients with Limited Small Cell Lung Cancer Also Receiving Cisplatin or Carboplatin and Etoposide
Anatomic Site:
Lung
Histology:
Small-Cell Lung Cancer (SCLC)
Mutation:
None
Stage:
Limited Stage
Treatment Phase:  Histologically or cytologically documented SCLC restricted to one hemiothorax. Patient may have received one and only one cycle of chemotherapy.
Trial Phase:
III
Trial Type:
Treatment
Principal Investigator:
Rameses Sroufe, MD
Formal Study Name:  A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Placebo for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
Anatomic Site:
Lung
Histology:
Non-Small Cell Lung Carcinoma, Non-Small Cell Lung Cancer (NSCLC)
Mutation:
Fusion
Stage:
Carcinoma: Stage IB, Stage IIA, Stage IIB; NSCLC: Stage IIIA
Treatment Phase:  Patients have undergone complete surgical resection of their cancer and have negative margins and registered to A151216.
Trial Phase:
III
Trial Type:
Treatment
Principal Investigator:
Todd Robbins, MD
Formal Study Name:  A Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer
Anatomic Site:
Lung
Histology:
Squamous
Mutation:
None
Stage:
Stage IV
Treatment Phase:  Must have completed at least one round of treatment
Trial Phase:
II/III
Trial Type:
Treatment
Principal Investigator:
Raymond Osarogiagbon, MD
Formal Study Name:  A Phase II Study of Talazoparib (BMN 673) in Patients with Homologous Recombination Repair Deficiency Positive Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study)
Anatomic Site:
Lung
Histology:
Squamous Cell Carcinoma
Mutation:
Mutation in any one of the following critical HRR pathway genes: ATM, ATR, BARD1, BRCA1, BRCA2, BRIP1, CHEK1, CHEK2, FANCA, FANCC, FANCD2, FANCF, FANCM, NBN (NBS1), PALB2, RAD51, RAD51B (RAD51L1), RAD54L, RPA1
Stage:
Stage IV
Treatment Phase:  Patients must have achieved stable disease, a partial response, or a complete response at their first disease assessment after initiating firstline platinum-based chemotherapy.
Trial Phase:
II
Trial Type:
Treatment
Principal Investigator:
Raymond Osarogiagbon, MD